<DOC>
	<DOCNO>NCT01537081</DOCNO>
	<brief_summary>The study design meet regulatory requirement outside US . The dose regimen assessment timepoints dictate immediate release ( IR ) guaifenesin ( GGE ) match approve Mucinex label U.S . The purpose study determine whether Mucinex effective non-inferior compare placebo immediate release guaifenesin treatment symptom acute upper respiratory infection . This design require base EU regulatory guidance .</brief_summary>
	<brief_title>Safety Efficacy Mucinex IR Guaifenesin Treatment Symptoms Acute Upper Respiratory Tract Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine , phenylpropanolamine drug combination</mesh_term>
	<criteria>1 . Has develop cold symptom within 3 day prior dose Day 1 . 1 . Chronic illness . 2 . Febrile illness &gt; 101 F within 7 day prior Day 1 , 3 . Pregnant . 4 . Known current malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>